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Background: The aims of this study were to determine the 5-year incidence of posterior capsule opacification
(PCO) requiring Nd:YAG laser capsulotomy in a representative mixed cohort of cataract patients, to determine risk
factors for PCO and to investigate possible association with growth of human lens epithelial cells (HLEC) in vitro.
Methods: Pieces of the anterior lens capsule and adhering HLEC were obtained at cataract surgery and cultured
individually. After one and two weeks respectively, cultured cells were stained with carboxy-fluorescein diacetate
succinimidyl ester (CFDA SE), after which image processing software was used to determine the area of the
confluent cell layer. The 5-year incidence of Nd:YAG laser capsulotomy in this cohort was determined through
medical records and by mail or telephone interviews. For statistic analyses Mann–Whitney U-test, Fisher’s exact test
and binary logistic regression were used.
Results: Data on treatment/no treatment for PCO was obtained from 270 patients with a median follow-up time
of 57 months (range 50–64 months). The three-year cumulative incidence of PCO was 5.2% and the cumulative
5-year incidence was 11.9%. Patients who had undergone Nd:YAG laser capsulotomy were significantly younger
(median 71 years) than patients who did not receive treatment for PCO (median 75 years, p = 0.022). Logistic
regression demonstrated that apart from younger age, follow-up time and type of intraocular lens (IOL) were
associated with risk of PCO, with hydrophilic 1-piece IOLs conferring a higher risk than hydrophobic acrylic 1-piece or
3-piece IOLs (adjusted OR = 9.4, 95% CI 2.5-35.7, p = 0.001). Of the 270 patients from whom information could be
retrieved regarding PCO treatment, in vitro cell culture could be established and quantified from 185 patients. No
significant difference in cell growth in vitro was shown between patients subsequently requiring/not requiring Nd:
YAG laser capsulotomy.
Conclusions: The cumulative 5-year incidence of 11.9% is comparable or slightly higher than reported in other
recent studies. The type of IOL was the most important risk factor for PCO in this study, whereas intrinsic proliferative
capacity of the individual’s lens epithelial cells seems to be less important for subsequent PCO development.
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Although cataract surgery in most patients is a standard
procedure with low complication rates, posterior capsule
opacification (PCO) remains a relatively common condition
postoperatively [1]. In a majority of patients, PCO can easily
be treated with neodymium-doped yttrium aluminium gar-
net (Nd:YAG) laser capsulotomy. However, this treatment
can itself result in complications such as raise in intraocular
pressure, inflammation, cystoid macular edema or retinal
detachment [2,3]. Many approaches have been tried in
order to prevent PCO, both pharmacological or cytotoxic
measures to affect lens cell viability, different materials and
design of the intraocular lens (IOL) and various surgical
strategies [1,4]. However, so far the only preventive measure
to reduce PCO with solid evidence is a square edged design
of the IOL [5]. The first studies on PCO incidence with this
type of IOL showed promising results and it was generally
considered that the problem of PCO was a matter of the
past [6,7]. Since then, studies with longer follow-up have
demonstrated that PCO incidence is still high, suggesting
that a square edged IOL may delay the onset of PCO but
the problem is far from solved [1,8].
Previous epidemiologic studies have indicated that
individual-related factors such as age, gender and ocu-
lar comorbidity may influence the risk of PCO [9-11].
However, the relative contribution of such individual-
related risk factors to risk of PCO in comparison with
IOL- or surgery-related factors is not known. Also, it is
not known whether individual-related factors that pro-
mote PCO development are due to intrinsic properties
of the lens epithelial cells of that individual or if they are
due to individual-dependent systemic factors or differences
in the ocular milieu surrounding the lens cells in vivo.
We therefore set up a study investigating the proliferative
capacity of individual lens epithelium capsule specimens
in vitro and compared this to the risk of experiencing Nd:
YAG laser posterior capsulotomy during a 5-year follow-up
period. In addition, the 5-year incidence of PCO requiring
Nd:YAG laser capsulotomy in a representative cohort of
cataract patients in a tertiary eye clinic is reported.
Methods
In 2007, human lens capsule epithelium specimens were
collected from 356 patients during cataract surgery at
the Eye Clinic, Sahlgrenska University Hospital, Mölndal.
The study was approved by The Regional Ethics Committee
in Gothenburg, Västra Götaland County, Sweden, and
the tenets of the Declaration of Helsinki were followed.
All patients gave informed consent. Collection of specimens
and subsequent cell culture was performed as previously
described [12]. Briefly, the human lens epithelium speci-
mens were immediately after surgery put in Eppendorf
tubes with standard culture medium (RPMI-1640) sup-
plemented with 10% fetal calf serum (FSC), 100 U ml−1penicillin, 0.1 mg ml−1 streptomycin and 2 mM L-glutamine.
After storage in room temperature for up to 24 hours,
the lens capsule epithelium specimens were transferred
to 24-well culture dishes (TPP, Switzerland) containing
freshly prepared cell culture medium supplemented with
5% FCS. No attempts were made to orient the capsules
with one specific side downwards, nor to attach the capsules
to the plastic bottom. Instead the capsules were allowed to
set freely to the bottom of the culture well. The culture
dishes were then put into a humidified CO2-incubator
at 37°C. After one week, a majority of the lens capsule
epithelium specimens, which were approximately 5 mm
in diameter, had attached to the bottom of the culture
wells and lens cells had started to proliferate and to grow
outside the capsule. Cell cultures were subsequently incu-
bated with carboxy-fluorescein diacetate succinimidyl ester
(CFDA SE) for 15 minutes at room temperature. CFDA
SE (Vybrant CFDA SE, Invitrogen, Eugene, OR, USA)
is a fluorogenic non-toxic compound that only enters
metabolically active cells. Prior to staining, a stock solution
of 10 mM CFDA SE was prepared in dimethyl sulfoxide
(DMSO). This stock solution was then further diluted
to 10 μM in preheated phosphate buffered saline (PBS).
After 15 minutes the CFDA SE solution was replaced by
freshly prepared cell culture medium with 5% FCS and
lens capsule epithelium specimens were photographed
using a confocal microscope (Nikon Eclipse TE300 C1),
excitation wavelength 492 nm, emission wavelength 517 nm.
One week after the first staining procedure, fluores-
cence had faded and cells were again incubated with
CFDA SE and photographed as above. Images were cap-
tured with a Nikon D-Eclipse C1 camera and EZ-C1
3.30 Gold as imaging software.
In 2012, five years after collection and cell culture of the
lens capsule specimens, medical records were studied
in order to establish if the patients had been subjected
to Nd:YAG laser capsulotomy due to posterior capsule
opacification. Since this procedure is performed in several
eye clinics in the Gothenburg area, letters were sent to
all patients who had not had Nd:YAG laser capsulotomy
at the Sahlgrenska Eye Clinic, inquiring about PCO
treatment elsewhere. Patients not responding by mail
were also contacted by telephone. An additional ethical
permission was obtained from The Regional Ethics
Committee in Gothenburg, Västra Götaland County,
Sweden, for the follow-up part of the study before con-
tact was taken with any patients. During the five year
follow-up period, 51 persons (14.8%) were deceased.
No contact was taken with relatives to the deceased
persons in order to inquire about Nd:YAG capsulotomy
and hence these persons were excluded from the study. In
addition, 35 patients could not be reached and were also
excluded, leaving a number of 270 patients from whom re-
liable information about PCO treatment could be obtained.




(n = 235) (n = 35)
Age at surgery, median (10th-90th percentiles), N = 270 75 (58.6-83.0) 71 (44.0-81.4) 0.022*
Female gender, n (%), N = 270 157 (66.8) 24 (68.6) 1.00†
Pseudoexfoliations
48 (21.7) 9 (25.7) 0.66†present preoperatively,
n (%), N = 256
Uveitis diagnosis prior to cataract surgery, n (%), N = 256 7 (3.2) 1 (2.9) 1.00†
Diabetes prior to cataract surgery, n (%), N = 255 17 (7.7) 5 (14.7) 0.188†
Type of IOL, n (%), N = 268
− Tecnis ZA9003 85 (36.5) 8 (22.9)
− SN60AT 75 (32.2) 8 (22.9)
− Acrysof SN60WF 64 (27.5) 10 (28.6)
− MA60MA 1 (0.4) 0 (0.0)
− Akreos Adapt 2 (0.9) 2 (5.7)
− Akreos MI60 4 (1.7) 6 (17.1)
− Acrismart 1 (0.4) 0 (0.0)
− Hoya PY-60 AD 1 (0.4) 1 (2.9)
Additional topical 20 (8.5) 3 (8.6) 1.00†
anti-inflammatory
treatment postoperatively‡
n (%), N = 270
IOL = intraocular lens, Nd:YAG = neodymium-doped yttrium aluminium garnet.
*Mann–Whitney U-test.
†Fisher’s exact test.
‡Topical anti-inflammatory treatment postoperatively in addition to 1% dexamethasone 3 times daily for 3 weeks.
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foliations, uveitis, diabetes, type of IOL and topical
anti-inflammatory treatment postoperatively. Several
types of IOL were used during the period when lens
capsule specimens were collected; Tecnis ZA9003
(Abbott Medical Optics, CA, USA), AcrySof SN60AT,
SN60WF and MA60MA (Alcon Inc, TX, USA), Akreos
Adapt and Akreos MI60 (Bausch & Lomb, NY, USA),Table 2 Multivariate analysis of possible risk factors for requi




Hydrophobic 3-piece IOL‡ −0.014
Hydrophobic 1-piece IOL# 0.014
Hydrophilic 1-piece IOL|| 2.246
OR = adjusted odds ratio, CI = confidence interval, IOL = intraocular lens.
*Binary logistic regression with Nd:YAG capsulotomy treatment as dependent variab
†Age at cataract surgery.
‡Tecnis ZA9003, (n = 93).
#Acrysof SN60WF/SN60AT, (n = 157).
||Akreos Adapt/Akreos MI60, (n = 14).Acri.Smart 36A (Acri.Tec, Carl Zeiss Meditec AG,
Germany, recently renamed the CT Asphina 509 M)
and Hoya PY-60 AD (Hoya Corporation, Japan). For
statistical analysis of the influence of IOL type on PCO
incidence, IOLs that were only used in a single patient were
not included. The remaining IOLs were grouped accord-
ingly; 1) hydrophobic acrylic 3-piece IOL (Tecnis ZA9003),
2) hydrophobic acrylic 1-piece IOLs (AcrySof SN60ATring Nd:YAG laser capsulotomy, N = 264
dard error OR 95% CI P-value*
0.018 0.957 0.924 – 0.991 0.014
0.434 0.760 0.325 – 1.780 0.528
0.057 1.165 1.042 – 1.303 0.007
0.479 0.986 0.386 – 2.520 0.977
0.479 1.014 0.397 – 2.592 0.977
0.679 9.448 2.498 – 35.737 0.001
le and age, male gender, follow-time and type of IOL as covariates.
Figure 1 (See legend on next page.)
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Figure 1 Kaplan-Meier survival plots of eyes not requiring Nd:YAG laser posterior capsulotomy. Patients are censored at the end of
follow-up. For the whole study group, 268 patients were included at the beginning of the period (A). Patients were also stratified according to
IOL type (B). Only IOLs used in more than one patient were included, yielding a number of 264 patients. The IOLs were then subtyped accordingly:
1) hydrophobic acrylic 3-piece IOL (Tecnis ZA9003) n = 93, 2) hydrophobic acrylic 1-piece IOLs (AcrySof SN60AT and SN60WF) n = 157, 3) hydrophilic
acrylic 1-piece IOLs (Akreos Adapt and Akreos MI60) n = 14.
Figure 2 Growth of human lens epithelium cells from
capsulorhexis specimens in culture. The lens explants were
stained with carboxy-fluorescein diacetate succinimidyl ester
(CFDA SE) after one (A) and two weeks (B) of cell culture and
photographed with a confocal microscope (Nikon Eclipse TE300 C1),
excitation wavelength 492 nm, emission wavelength 517 nm.
Scale bar = 2 mm.
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(Akreos Adapt and Akreos MI60). All of these IOLs had
a sharp edge design of the optic.
Statistics
The area of the fluorescent lens capsule epithelium
specimens was determined after one and two weeks of
culture using image processing software (ImageJ, National
Institutes of Health, USA) and the increase in cell layer
surface was calculated. Since the increase in cell growth
was not normally distributed, Mann–Whitney U-test was
used for comparison of cell growth between the group
subjected to Nd:YAG laser capsulotomy and the group
not requiring PCO treatment. For statistic analysis of
demographic characteristics Mann–Whitney U-test and
Fisher’s exact test were used. Kaplan-Meier survival
plots were constructed for cumulative incidence of
eyes not requiring Nd:YAG laser capsulotomy, where
patients were censored at the end of follow-up period.
Survival plots were also generated after stratification
for type of IOL. Binary logistic regression with Nd:
YAG capsulotomy as dependent variable was performed
in a backward stepwise model with age at cataract surgery,
gender, follow-up time, PEX, uveitis, diabetes, type of IOL
and topical anti-inflammatory treatment as covariates.
Significant parameters, along with age and gender,
were then included in the final model. Significance was
set at P < 0.05. SPSS 16.0 (SPSS Inc, Chicago, Il) was
used as statistic software.
Results
Medical records or written/oral statements regarding
treatment of posterior capsule opacification (PCO)
were obtained from 270 patients who had experienced
cataract surgery at the Eye Clinic at Sahlgrenska University
Hospital, Mölndal, in 2007. Demographic data is presented
in Table 1. Patients who had undergone Nd:YAG laser
capsulotomy were significantly younger (median 71 years)
than patients who did not receive treatment for PCO
(median 75 years, p = 0.022). Logistic regression also
confirmed that younger age was significantly associ-
ated with risk of requiring Nd:YAG laser capsulotomy
(adjusted OR = 0.96, 95% CI 0.92-0.99, p = 0.014), see
Table 2. Median follow-up time in this study was 57 months
(range 50–64 months) and during this period 35 patients
(13%) were subjected to Nd:YAG laser capsulotomy.
Kaplan-Meier survival plots for eyes not requiring Nd:YAG laser posterior capsulotomy are presented in Figure 1.
The three-year cumulative incidence for the whole study
group was 5.2% whereas the five-year cumulative incidence
was 11.9%. Stratification for type of IOL revealed major
differences in Nd:YAG rates (Figure 1B) with the hydro-
philic acrylic IOL group having a significantly higher PCO-
incidence (adjusted OR = 9.4, 95% CI 2.5-35.7, p = 0.001).
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retrieved regarding PCO treatment, in vitro cell culture
could be established and quantified from 185 patients.
These patients included those where no cell growth
could be detected but where the capsule specimen was
attached to the culture dish. See Figure 2 for appearance of
representative lens capsule explant after one and two weeks
of culture. No significant difference in cell growth in vitro
was seen between patients treated with or not treated
with Nd:YAG laser capsulotomy (p = 0.24, Mann–Whitney
U test, Figure 3).
Discussion
An often cited meta-analysis by Schaumberg et al. from
1998 reported pooled estimates of the proportion of eyes
developing visually significant PCO of 11.8% (at 1 year
postoperatively), 20.7% (at 3 years) and 28.4% (at 5 years)
[13]. However, there was a wide range among published
PCO rates; for the 5-year incidence the PCO rate varied
between 18.4% and 38.4%. Recent studies have reported
incidence numbers of PCO requiring Nd:YAG laser
capsulotomy between 2% and 29%, depending on the
follow-up period and the type of IOL [8,14-16]. Although
this is slightly lower than the previously reported PCO-rate,
development of PCO remains the most common postop-
erative complication to cataract surgery, affecting a large
number of patients.
The overall 3-year and 5-year incidences of PCO in
this study were 5.2% and 11.9% respectively. These
numbers demonstrate that a large proportion of theFigure 3 Growth of human lens epithelium cells in vitro in relation to
cells in vitro as % of increase in cell area. Median (bar), interquartile range (
shown. No significant differences between in vitro cell growth of lens cells
Nd:YAG laser capsulotomy (n = 162) was seen (p = 0.24, Mann–Whitney U tpatients requiring Nd:YAG laser capsulotomy develop
vision-impairing PCO after the first three years, alter-
natively that they don’t get access to appropriate
treatment until after this time period. Either way, it is
important to bare in mind when determining PCO in-
cidence or when designing prospective randomized
studies with PCO as outcome that a long term follow-
up is essential.
A multivariate analysis of possible risk factors for PCO
showed that age, follow-up time and type of IOL were
significantly associated with risk of requiring Nd:YAG
laser capsulotomy. Median age in the group not treated
with Nd:YAG laser capsulotomy was 75 years as opposed
to 71 years in the group requiring PCO treatment. The
increased risk of PCO in younger patients is well known
from previous studies, especially in children where special
measures have to be taken, i.e. posterior capsulorhexis
and anterior vitrectomy, to prevent PCO development
[17]. However, even for the age group in the present
study, ranging from 32 to 90 years with an interquartile
range of 65 to 80 years, it is evident that age has a major
impact on the risk of experiencing PCO.
In the same multivariate analysis, the risk of requiring
Nd:YAG laser capsulotomy showed a strong association
with type of IOL (adjusted OR 9.4 [95% CI 2.5-35.7]).
The group with hydrophilic 1-piece IOL (Akreos) exhib-
ited a significantly increased risk of developing visually
significant PCO with an incidence of 57.1% as compared to
8.6% in the group with hydrophobic 3-piece IOL (Tecnis)
and 11.5% in the group with hydrophobic 1-piece IOLNd:YAG-treatment. Box-plot showing the growth of lens epithelial
boxes) and 95% confidence interval (error bars) as well as outliers are
derived from patients later treated with (n = 23) or not treated with
est).
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a sharp edge design. The present results are in accordance
with a prospective study by Heatley et al. in which pa-
tients were randomized to receive either a hydrophobic
(Acrysof SN60AT) or a hydrophilic (Centerflex 570H)
acrylic 1-piece IOL in the first eye and then received
the alternate IOL in the second eye. After one year the
area of PCO as assessed from photographs and im-
aging software was 4.9% in the hydrophobic IOL group
and 50.3% in the hydrophilic IOL group [18]. Another
study exhibited Nd:YAG rates after two-years follow-up of
10% for a hydrophobic (Acrysof SN60WF) and 42% for a
hydrophilic (BL27) acrylic IOL [19].
In this study, the proliferative capacity of lens epithelium
capsule specimens from 356 patients was determined using
in vitro cell culture technique. Of the 270 patients surviving
the follow-up period and from whom reliable information
regarding treatment with Nd:YAG laser capsulotomy could
be obtained, cell growth/or lack of cell growth could be
assessed for 185 patient samples. No significant differ-
ence in cell growth could be seen between specimens
derived from patients who later underwent Nd:YAG
laser capsulotomy and from those who didn’t. These find-
ings indicate that the inherent proliferative capacity of lens
epithelium cells from the donors is not a major contributor
to the risk of PCO development in vivo. Instead, cell
proliferation leading to visually significant PCO may
be more dependent on the local milieu, like the pres-
ence of growth factors which in turn may depend on
the degree of intraocular inflammation, or on physical
factors promoting cell proliferation, adhesion and migration
such as the configuration of the capsule, the capsule/IOL
interface and the IOL material.
Conclusions
Individual differences in intrinsic proliferative capacity
of the lens epithelium cells is less important for risk of
developing PCO than extrinsic factors. Efforts on pre-
venting PCO should therefore continue to focus on the
material and design of the IOL or on other mechanical
and chemical strategies.
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